Alterity Therapeutics Highlights New Publications On ATH434 In Parkinson's Disease

Alterity Therapeutics's ATHE data in an animal model of Multiple System Atrophy (MSA) were published in the Journal of Parkinson's Disease. 

• The publication describes a study evaluating the efficacy of ATH434 in genetically altered mice that develop manifestations of MSA. 
• The investigation demonstrated that ATH434 treatment reduced both the toxic oligomeric and aggregated forms of α–synuclein, a central nervous system protein essential for the normal function of nerve cells. 
• At the same time, ATH434 treatment reduced the cardinal pathology of MSA (glial cell inclusions), reduced brain iron, preserved neurons, and improved motor performance. 
• Previous studies with ATH434 in preclinical models of Parkinson's disease have shown that it is brain-penetrant, reduces iron accumulation and iron-mediated redox activity, provides neuroprotection, inhibits α–synuclein aggregation, and improves motor function. 
• The compound was also well-tolerated in a first-in-human oral dosing study in healthy and older adult volunteers with a favorable, dose-dependent pharmacokinetic profile.
• Price Action: ATHE shares are up 7.75% at $0.83 during the market session on the last check Friday.